Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial

American Heart Journal

Volumn 195, Issue , 2018, Pages 108-114

  Clark, Nathan P ^a   Douketis, James D ^b   Hasselblad, Vic ^c   Schulman, Sam ^b   Kindzelski, Andrei L ^d   Ortel, Thomas L ^e  

^a KAISER PERMANENTE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DALTEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; WARFARIN; ANTICOAGULANT AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CEREBROVASCULAR ACCIDENT; COMPLICATION; INCIDENCE; NORTH CAROLINA; POSTOPERATIVE HEMORRHAGE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT WITHDRAWAL;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DALTEPARIN; DOUBLE-BLIND METHOD; ELECTIVE SURGICAL PROCEDURES; FEMALE; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MALE; NORTH CAROLINA; POSTOPERATIVE HEMORRHAGE; STROKE; WARFARIN; WITHHOLDING TREATMENT;

EID: 85033402543     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.09.015     Document Type: Article

References (23)

1. Healey, J.S., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 126:3 (2012), 343–348.
2. Sherwood, M.W., et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 129:18 (2014), 1850–1859.
3. Garcia, D., et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 124:25 (2014), 3692–3698.
4. Douketis, J.D., et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:2 Suppl (2012), e326S–e350S.
5. Ageno, W., et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:2 Suppl (2012), e44S–e88S.
6. Douketis, J.D., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373:9 (2015), 823–833.
7. Halbritter, K.M., et al. Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost 3:12 (2005), 2823–2825.
8. Douketis, J.D., Perioperative management of warfarin therapy: to bridge or not to bridge, that is the question. Mayo Clin Proc 83:6 (2008), 628–629.
9. Gould, M.K., et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:2 Suppl (2012), e227S–e277S.
10. Cohen, A.T., Wagner, M.B., Mohamed, M.S., Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis. Am J Surg 174:1 (1997), 1–5.
11. Devereaux, P.J., et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 370:16 (2014), 1494–1503.
12. Tafur, A.J., et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 10:2 (2012), 261–267.
13. Omran, H., et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 108:1 (2012), 65–73.
14. Hammerstingl, C., et al. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. Cardiovasc Ther 27:4 (2009), 230–238.
15. Schulman, S., et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:1 (2010), 202–204.
16. Allison, P.D., Survival analysis using the SAS® system: a practical guide. 1995, SAS Institute, Cary, North Carolina.
17. Pisters, R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:5 (2010), 1093–1100.
18. Fang, M.C., et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 58:4 (2011), 395–401.
19. Gage, B.F., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151:3 (2006), 713–719.
20. O'Brien, E.C., et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 36:46 (2015), 3258–3264.
21. Burger, W., et al. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis.[see comment]. J Intern Med 257:5 (2005), 399–414.
22. Vittinghoff, E., McCulloch, C.E., Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165 (2007), 710–718.
23. Anonymous, Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. [see comment] Lancet 355:9212 (2000), 1295–1302.